Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15388149 | 0.88 | AKT1 (0.62) | AKT1ADORA2A | |
| SCHEMBL9975955 | 0.86 | AKT1 (1.00) | AKT1 | |
| SCHEMBL9976192 | 0.78 | AKT1 (1.00) | AKT1 | |
| SCHEMBL9975954 | 0.72 | AKT1 (1.00) | AKT1 | |
| SCHEMBL12111633 | 0.70 | ALDH1A1 (0.57) | ADORA2A | |
| SCHEMBL12111579 | 0.70 | ALDH1A1 (0.57) | ADORA2A | |
| SCHEMBL12111674 | 0.70 | ALDH1A1 (0.57) | ADORA2A | |
| SCHEMBL12111559 | 0.70 | ALDH1A1 (0.57) | ADORA2A | |
| SCHEMBL15388462 | 0.70 | AKT1 (0.76) | AKT1 | |
| SCHEMBL15388312 | 0.69 | AKT1 (1.00) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651949-B1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | BAYER IP GMBH (DE) | 2015-07-15 | — | — | EP | disclosed |
| US-8987286-B2 | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20130310405-A1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| EP-2651949-A1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080237-A1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310405-A1 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY | PIK3CA, PIK3CD, PIK3CB | AKT1 26/4885ADORA2A 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.